Navigation Links
Amylin Pharmaceuticals Announces Date and Time Change to Previously Announced Presentation at the Credit Suisse 2011 Healthcare Conference
Date:11/9/2011

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced it has re-scheduled its presentation at the Credit Suisse 2011 Healthcare Conference in Phoenix to Thursday, November 10, 2011 at 3:00 p.m. MT/5:00 p.m. ET/2:00 p.m. PT. Previously, the presentation had been scheduled for Wednesday, November 9, 2011 at 11:30 a.m. MT/1:30 p.m. ET/10:30 a.m. PT. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
2. Amylin Pharmaceuticals to Present at the Credit Suisse 2011 Healthcare Conference
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
7. Amylin Pharmaceuticals to Webcast Second Quarter Results
8. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
9. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
10. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
11. Lilly Comments on Court Ruling in Amylin Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 ResMed (NYSE: RMD ), BMC ( ... Haven, Florida ) today announced they have agreed on a ... will be permitted to sell their existing products in exchange for ... payment to 3B to close the Florida ... admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... , Jan. 20, 2017 ARMO BioSciences, Inc., ... data on the Company,s lead investigational immuno-oncology drug AM0010 ... by the American Society of Clinical Oncology (ASCO), taking ... CA. "AM0010 induces the ... + T cells in the blood and tumors ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
Breaking Medicine Technology:
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... Phytocéane ... Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired ... Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel ... Dan Holtzclaw in media for its creos™ line of bone regenerative products. ... Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a variety of ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Doctor C LLC, ... attended the January ECRM trade show to continue the marketing and distribution of its ... supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. At ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years ... Betsy, the clinical trial has been life-saving as she has been on the ... Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but ...
Breaking Medicine News(10 mins):